Molecular Diagnostics Expansion Will Unlock Potential While Cost Challenges Persist
AN
AnalystConsensusTarget
Not Invested
Consensus Narrative from 6 Analysts
Published
13 May 25
Updated
15 Aug 25
AnalystConsensusTarget's Fair Value
US$326.50
11.7% undervalued intrinsic discount15 Aug
US$288.16
1Y
-8.9%7D
0.3%